Hedge Fund Database
The curated database of hedge funds that publish investor letters. Research by geography, strategy, and schools of thought.
| # | Fund | Strategy | Style | Geography | AUM | Latest Letter |
|---|---|---|---|---|---|---|
The curated database of hedge funds that publish investor letters. Research by geography, strategy, and schools of thought.
| # | Fund | Strategy | Style | Geography | AUM | Latest Letter |
|---|---|---|---|---|---|---|
As of Oct 23, 2026
The Osterweis Opportunity Fund returned -8.98% net of fees in the third quarter of 2026, slightly outperforming its benchmark, the Russell 2000 Growth Index, which declined -9.39%. Fund performance was aided by an overweight cash allocation and strong security selection in Health Care and Information Technology. Over the trailing twelve months, the fund delivered 22.39% net of fees compared to 12.05% for the index. The portfolio's overweight exposure to Industrials and zero weighting in Energy detracted from relative performance, while security selection in Health Care generated positive absolute returns against an index sector decline. Macroeconomic crosscurrents dominated small-cap market performance during the quarter, with investor sentiment weighed down by elevated interest rates and concerns over artificial intelligence infrastructure capital expenditures. Despite these headwinds, the managers view the broader economic backdrop as sound. Roughly half of all small-cap companies reported earnings growth exceeding 20%, creating an increasingly attractive valuation disparity relative to large-cap equities, where massive data center investments may begin to constrain free cash flow generation. Portfolio management actively repositioned key sector exposures during the quarter. Within Information Technology, capital was rotated out of Phase I semiconductor infrastructure holdings like MACOM Technology Solutions toward Phase II software beneficiaries such as Twilio and Rubrik. In Health Care, profits were harvested from high-valuation life sciences to fund allocations to medical device makers, including top contributor AtriCure, while exposure to Alignment Healthcare was significantly reduced following margin and regulatory headwinds.
Identify innovative, secular small-cap growth companies with robust business fundamentals and attractive valuations capable of compounding value across full market cycles.
The managers maintain a constructive near-to-medium-term outlook, expecting durable small-cap earnings growth and compelling relative valuations to challenge recent large-cap market dominance.
Moderate Conviction Bullish
Market Conviction
Growth Outlook
Risk Appetite
Capital Deployment
Forward Guidance
Language Signal
Perceived Risk
Opportunity Density
Time Horizon
Top Conviction Themes
Key Catalysts
Every insight in this database connects to the original source. Read the actual thesis, see the actual concerns, and make your own call.
Buyside Digest has no business relationship, partnership, agency, sponsorship, endorsement, or affiliation with The Osterweis Opportunity Fund or any other manager whose content appears on the Service, except where expressly stated. We do not receive Manager Content directly from managers in most cases; content is collected from publicly available sources. Managers have not necessarily reviewed, approved, authorized, or endorsed our display of their content, our editorial commentary, our metadata extraction, or our classifications. Use of a manager’s name is for accurate attribution and identification purposes only, under principles of nominative fair use.
Buyside Digest does not independently verify the regulatory status, registrations, licensing, qualifications, credentials, or professional standing of managers whose content appears on the Service. We do not represent that managers are properly registered with applicable regulatory bodies, that their content complies with applicable securities laws, or that their performance representations are accurate. Inclusion of a manager in our database is based on the publicly available nature of their content, not on our verification of their regulatory status or content compliance. Users are responsible for conducting their own due diligence on any manager.
Performance data, returns, assets under management (“AUM”), and similar figures displayed on this page are sourced from publicly available manager communications (including investor letters), public filings, or other third-party sources. Buyside Digest does not independently verify performance figures, calculate returns, or audit manager-reported data. Such figures: May be selectively reported by the manager; May use non-standard calculation methodologies; May not reflect fees, expenses, taxes, or other costs; May be inconsistent across reporting periods; May be outdated. Past performance is not indicative of future results. Performance figures should not be relied upon for investment decisions without independent verification. Users should request audited performance data directly from the manager and conduct their own due diligence.